An in vivo evaluation of the antiseizure activity and acute neurotoxicity of agmatine

Pharmacology Biochemistry and Behavior

Volumn 74, Issue 3, 2003, Pages 771-775

  Bence, Aimee K ^a   Worthen, David R ^a   Stables, James P ^b   Crooks, Peter A ^a  

^a University of Kentucky   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Acute neurotoxicity; Agmatine; Anticonvulsant activity; Epilepsy; Maximal electroshock; Seizure

Indexed keywords

AGMATINE; ANTICONVULSIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG SCREENING; ELECTRIC SHOCK; IN VIVO STUDY; MALE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; SEIZURE;

EID: 0037307143     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(02)01079-1     Document Type: Article

References (31)

1. Anis N., Sherby S., Goodnow R. Jr., Niwa M., Konno K., Kallimopoulos T.et al. Structure-activity relationships of philanthotoxin analogs and polyamines on N-methyl-D-aspartate and nicotinic acetylcholine receptors. J. Pharmacol. Exp. Ther. 254:1990;764-773.
2. Baudry M., Lynch G., Gall C. Induction of ornithine decarboxylase as a possible mediator of seizure-elicited changes in genomic expression in rat hippocampus. J. Neurosci. 6:1986;3430-3435.
3. Chapman A.G. Glutamate and epilepsy. J. Nutr. 130:2000;1043S-1045S.
4. Dunham M.S., Miya T.A. A note on a simple apparatus for detecting neurological deficit in rats and mice. J. Am. Pharm. Assoc. (Sci. Ed.). 46:1957;208-209.
5. Gonzalez C., Regunathan S., Reis D.J., Estrada C. Agmatine, an endogenous modulator of noradrenergic neurotransmission in the rat tail artery. Br. J. Pharmacol. 119:1996;677-684.
6. Halaris A., Zhu H., Feng Y., Piletz J.E. Plasma agmatine and platelet imidazoline receptors in depression. Ann. N.Y. Acad. Sci. 881:1999;445-451.
7. Hayashi Y., Hattori Y., Moriwaki A., Lu Y.F., Hori Y. Increases in brain polyamine concentrations in chemical kindling and single convulsion induced by pentylenetetrazol in rats. Neurosci. Lett. 149:1993;63-66.
8. Kolesnikov Y., Jain S., Pasternak G.W. Modulation of opioid analgesia by agmatine. Eur. J. Pharmacol. 296:1996;17-22.
9. Laschet J., Trottier S., Leviel V., Guibert B., Bansard J.Y., Chauvel P.et al. Heterogenous distribution of polyamines in temporal lobe epilepsy. Epilepsy Res. 35:1999;161-172.
10. Li G., Regunathan S., Barrow C.J., Eshraghi J., Cooper R., Reis D.J. Agmatine: an endogenous clonidine-displacing substance in the brain. Science. 263:1994;966-969.
11. McKay B.E., Lado W.E., Martin L.J., Galic M.A., Fournier N.M. Learning and memory in agmatine-treated rats. Pharmacol. Biochem. Behav. 72:2002;551-557.
12. Meldrum B.S., Akbar M.T., Chapman A.G. Glutamate receptors and transporters in genetic and acquired models of epilepsy. Epilepsy Res. 36:1999;189-204.
13. 2-imidazoline binding sites. Naunyn Schmiedebergs Arch. Pharmacol. 351:1995;507-516.
14. Onal A., Soykan N. Agmatine produces antinociception in tonic pain in mice. Pharmacol. Biochem. Behav. 69:2001;93-97.
15. Otake K., Ruggiero D.A., Regunathan S., Wang H., Milner T.A., Reis D.J. Regional localization of agmatine in the rat brain: an immunocytochemical study. Brain Res. 787:1998;1-14.
16. Petty W.C., Karler R. The influence of aging on the activity of anticonvulsant drugs. J. Pharmacol. Exp. Ther. 150:1965;443-448.
17. Pinthong D., Hussain J.F., Kendall D.A., Wilson V.G. Comparison of the interaction of agmatine and crude methanolic extracts of bovine lung and brain with alpha 2-adrenoceptor binding sites. Br. J. Pharmacol. 115:1995;689-695.
18. Raasch W., Regunathan S., Li G., Reis D.J. Agmatine is widely and unequally distributed in rat organs. Ann. N.Y. Acad. Sci. 763:1995;330-334.
19. Raasch W., Regunathan S., Li G., Reis D.J. Agmatine, the bacterial amine, is widely distributed in mammalian tissues. Life Sci. 56:1995;2319-2330.
20. Raasch W., Schafer U., Chun J., Dominiak P. Biological significance of agmatine, an endogenous ligand at imidazoline binding sites. Br. J. Pharmacol. 133:2001;755-780.
21. Reis D.J., Regunathan S. Is agmatine a novel neurotransmitter in brain? Trends Pharmacol. Sci. 21:2000;187-193.
22. Reis D.J., Yang X.C., Milner T.A. Agmatine containing axon terminals in rat hippocampus form synapses on pyramidal cells. Neurosci. Lett. 250:1998;185-188.
23. Sastre M., Regunathan S., Galea E., Reis D.J. Agmatinase activity in rat brain: a metabolic pathway for the degradation of agmatine. J. Neurochem. 67:1996;1761-1765.
24. Satriano J., Matsufuji S., Murakami Y., Lortie M.J., Schwartz D., Kelly C.J.et al. Agmatine suppresses proliferation by frameshift induction of antizyme and attenuation of cellular polyamine levels. J. Biol. Chem. 273:1998;15313-15316.
25. Stables J.P., Kupferberg H.J. The NIH anticonvulsant drug development (ADD) program: preclinical anticonvulsant screening project. Avanzini G., Tanganelli P., Avoli M. Molecular and cellular targets for antiepileptic drugs. 1997;191-198 John Libby & Company, London.
26. Tabor C.W., Tabor H. Polyamines. Annu. Rev. Biochem. 53:1984;749-790.
27. Uzbay I.T., Yesilyurt O., Celik T., Ergun H., Isimer A. Effects of agmatine on ethanol withdrawal syndrome in rats. Behav. Brain Res. 107:2000;153-159.
28. Vargiu C., Cabella C., Belliardo S., Cravanzola C., Grillo M.A., Colombatto S. Agmatine modulates polyamine content in hepatocytes by inducing spermidine/spermine aceltyltransferase. Eur. J. Biochem. 259:1999;933-938.
29. White H.S., Johnson M., Wolf H.H., Kupferberg H.J. The early identification of anticonvulsant activity: role of the maximal electroshock and subcutaneous pentylenetetrazol seizure models. Ital. J. Neurol. Sci. 16:1995;73-77.
30. White H.S., Woodhead J.H., Franklin M.R., Swinyard E.A., Wolf H.H. Experimental selection, quantification, and evaluation of anticonvulsants. Levy R.H., Mattson R.H., Meldrum M.B. Antiepileptic drugs. 1995;99-110 Raven Press, New York.
31. Yang X.C., Reis D.J. Agmatine selectively blocks the N-methyl-D-aspartate subclass of glutamate receptor channels in rat hippocampal neurons. J. Pharmacol. Exp. Ther. 288:1999;544-549.